Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Medicare Rx Sets Up New Battle For Mail Vs. Retail: Any Willing Mail Plan?

  • News

Executive Summary

Medco expects to retain its typical role as exclusive mail-order supplier within plans it manages under Medicare Part D, despite language in the Medicare regs requiring plans to offer contracts to "any willing" mail provider

You may also be interested in...



CVS/Caremark Declares Mail V. Retail Truce; Will New Model Win The Peace?

The marriage of CVS and Caremark will blur the lines between traditional mail order and retail pharmacy services by providing a range of prescription dispensing options

CVS/Caremark Declares Mail V. Retail Truce; Will New Model Win The Peace?

The marriage of CVS and Caremark will blur the lines between traditional mail order and retail pharmacy services by providing a range of prescription dispensing options

Ovations/Walgreens Deal Reflects Importance Of Retail In Medicare Part D

Ovations' partnership with Walgreens on its Medicare prescription drug plan underscores the importance of a strong retail presence in the Part D market

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS045415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By